Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
Nanoscale
|
May 30, 2019
Enclosing classical polyoxometallates in silver nanoclusters
Zhi Wang, Yi-Ming Sun, Qing-Ping Qu, et al.
Nucleic Acids Research
|
August 9, 2011
Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data
Chia-Hung Chien, Yi-Ming Sun, Wen-Chi Chang, et al.
Acta Pharmacologica Sinica
|
December 8, 2020
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo
Meng-di Dai, Yue-Liang Wang, Jun Fan, et al.
Acta Pharmacologica Sinica
|
April 18, 2017
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors
Zhong-Min Yang, Xue-Mei Liao, Yi Chen, et al.
Acta Pharmacologica Sinica
|
January 26, 2016
DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
Meng-yuan Li, Yong-cong Lv, Lin-jiang Tong, et al.
Oncotarget
|
April 4, 2015
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition
Jun-Mei Yi, Xiao-Fei Zhang, Xia-Juan Huan, et al.
Acta Pharmacologica Sinica
|
March 30, 2021
SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
Xi Zhang, Yu-Ting Duan, Yi Wang, et al.
European Journal of Medicinal Chemistry
|
August 11, 2023
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities
Pingyuan Wang, Wen-Ting Zhu, Yajing Wang, et al.
Langmuir : the ACS Journal of Surfaces and Colloids
|
July 10, 2026
Controlled Precipitation and Microcoating Formation of Shellac via Sequential Ethanol-Water Solvent Exchange
Tanjina Sharmin, Toshihiro Takeshita, Sihyung Kim, et al.
Cancer Letters
|
July 14, 2018
Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
Xue-Ling Liu, Yi-Chao Xu, Yu-Xiang Wang, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
Nanoscale
|
May 30, 2019
Enclosing classical polyoxometallates in silver nanoclusters
Zhi Wang, Yi-Ming Sun, Qing-Ping Qu, et al.
Nucleic Acids Research
|
August 9, 2011
Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data
Chia-Hung Chien, Yi-Ming Sun, Wen-Chi Chang, et al.
Acta Pharmacologica Sinica
|
December 8, 2020
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo
Meng-di Dai, Yue-Liang Wang, Jun Fan, et al.
Acta Pharmacologica Sinica
|
April 18, 2017
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors
Zhong-Min Yang, Xue-Mei Liao, Yi Chen, et al.
Acta Pharmacologica Sinica
|
January 26, 2016
DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
Meng-yuan Li, Yong-cong Lv, Lin-jiang Tong, et al.
Oncotarget
|
April 4, 2015
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition
Jun-Mei Yi, Xiao-Fei Zhang, Xia-Juan Huan, et al.
Acta Pharmacologica Sinica
|
March 30, 2021
SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
Xi Zhang, Yu-Ting Duan, Yi Wang, et al.
European Journal of Medicinal Chemistry
|
August 11, 2023
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities
Pingyuan Wang, Wen-Ting Zhu, Yajing Wang, et al.
Langmuir : the ACS Journal of Surfaces and Colloids
|
July 10, 2026
Controlled Precipitation and Microcoating Formation of Shellac via Sequential Ethanol-Water Solvent Exchange
Tanjina Sharmin, Toshihiro Takeshita, Sihyung Kim, et al.
Cancer Letters
|
July 14, 2018
Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
Xue-Ling Liu, Yi-Chao Xu, Yu-Xiang Wang, et al.
Page
of 8